Humanized antihuman IL-6 receptor antibody, tocilizumab.
暂无分享,去创建一个
[1] F. Breedveld,et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.
[2] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[3] Y. Shima,et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.
[4] Y. Ohsugi,et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. , 2005, International immunopharmacology.
[5] P. Woo,et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.
[6] J. Saldanha,et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer research.
[7] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[8] P. Emery,et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.
[9] D. M. van der Heijde,et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.
[10] R. Price,et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.
[11] T. Hibi,et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.
[12] M. Cutolo,et al. Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .
[13] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[14] S. Tominaga,et al. Exacerbation of chronic active Epstein–Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody , 2006, Annals of the rheumatic diseases.
[15] J. Scheller,et al. Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer , 2006, Scandinavian journal of immunology.
[16] N. Nishimoto. Interleukin-6 in rheumatoid arthritis , 2006, Current opinion in rheumatology.